尼拉帕里布剂量降低对卵巢癌患者短期结果的影响
Matteo Bruno1, Adriana Ionelia Apostol1, Serena Maria Boccia1
1Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.
概括
在卵巢癌患者中,尼拉巴里布剂量降低是常见的,特别是在治疗的早期和第一线设置中. 然而,这些剂量修改似乎不会对无进展生存率产生负面影响.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 尼拉帕里布的维持疗法是卵巢癌的标准治疗方法.
- 尽管初始剂量是个性化的,但仍观察到尼拉帕里布剂量降低的高率.
- 了解剂量降低对疗效和安全的影响至关重要.
研究的目的:
- 评估尼拉帕里布剂量减少对卵巢癌患者无进展生存期 (PFS) 的影响.
- 为了比较原发性和复发性卵巢癌组之间的剂量减少率和安全概况.
- 为了确定尼拉帕里布剂量减少的预测因素.
主要方法:
- 215名接受尼拉帕里布维持治疗的卵巢癌患者 (2019-2022) 的回顾性评估.
- 分析尼拉帕里布剂量 (300/200毫克/天起始剂量) 和剂量减少 (200/100毫克/天).
- 评估减少率,不良事件,预测因素和PFS.
主要成果:
- 在前三个周期内,剂量减少经常发生 (67%的初级,45%的复发).
- 与初级组 (54.8%) 相比,复发组 (35.1%) 的3级以上的不良事件较少发生.
- 体重和之前的双化学疗法被确定为剂量降低的潜在风险因素.
结论:
- 尼拉帕里布剂量减少是常见的,特别是在初始治疗周期内的第一线设置中.
- 剂量调整在任何一组患者中都没有显著影响中位数无进展生存期.
- 进一步的研究可能会改进剂量策略,以优化尼拉帕里布治疗结果.
更多相关视频
相关概念视频
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
194
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
194